Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.48 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 8/20 | 0.42 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3007905 | 1.00 | ACE (0.49) | ACEITGA4ITGB7ITGB3ITGA2B | |
| SCHEMBL3007900 | 1.00 | ACE (0.49) | ACEITGA4ITGB7ITGB3ITGA2B | |
| SCHEMBL23824316 | 0.90 | CTSL (0.47) | ACEITGA4ITGB7CTSSCTSK | |
| SCHEMBL23824319 | 0.90 | CTSL (0.47) | ACEITGA4ITGB7CTSSCTSK | |
| SCHEMBL13301861 | 0.90 | ACE (0.39) | ACEITGA4ITGB7PPARAPPARG | |
| SCHEMBL24807994 | 0.89 | KLK5 (0.43) | ACEITGA4ITGB7CTSSCTSK | |
| SCHEMBL15729185 | 0.89 | KLK5 (0.43) | ACEITGA4ITGB7CTSSCTSK | |
| SCHEMBL10609619 | 0.89 | REN (0.41) | ACEITGA4ITGB7CTSSCTSK | |
| SCHEMBL634586 | 0.87 | ITGA4 (0.45) | ACEITGA4ITGB7 | |
| SCHEMBL6957298 | 0.85 | ACE (0.50) | ACEITGA4ITGB7ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216441-A1 | Farnesyltransferase inhibitors | WEINSTOCK, STEVEN F. | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216441-A1 | Farnesyltransferase inhibitors | FNTA, FNTB, LCAT | ACE 451/4885ITGA4 2694/4885ITGB7 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.